IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia
The interactions of antibodies with myeloid Fcγ receptors and the complement system are regulated by an Asn297-linked glycan in the Fc portion of IgG. Alterations of serum IgG-Fc glycosylation have been reported in various autoimmune diseases, and correlate with treatment response and disease activi...
Gespeichert in:
| Veröffentlicht in: | SCIENTIFIC REPORTS 2020-02, Vol.10 (1), p.3051, Article 3051 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 3051 |
| container_title | SCIENTIFIC REPORTS |
| container_volume | 10 |
| creator | Schmidt, David E. de Haan, Noortje Sonneveld, Myrthe E. Porcelijn, Leendert van der Schoot, C. Ellen de Haas, Masja Zwaginga, Jaap-Jan Wuhrer, Manfred Vidarsson, Gestur |
| description | The interactions of antibodies with myeloid Fcγ receptors and the complement system are regulated by an Asn297-linked glycan in the Fc portion of IgG. Alterations of serum IgG-Fc glycosylation have been reported in various autoimmune diseases, and correlate with treatment response and disease activity. We hypothesized that IgG-Fc glycosylation is altered in immune thrombocytopenia (ITP) and associates with response to anti-CD20 monoclonal antibody treatment (rituximab). IgG-Fc glycosylation was analyzed by liquid chromatography-mass spectrometry. We found that IgG-Fc glycosylation was identical between refractory ITP patients (HOVON64 trial; N = 108) and healthy controls (N = 120). Two months after rituximab treatment, we observed a shift in Fc glycosylation, with a mean 1.7% reduction in galactosylation for IgG1 and IgG4 and a mean 1.5% increase for bisection in IgG1, IgG2/3 and IgG4 (adjusted p |
| doi_str_mv | 10.1038/s41598-020-59651-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_473316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2359370440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-f2afffbd05290e8b2f11cf805726768738aa7ef9600daff4fef88df77706a0f63</originalsourceid><addsrcrecordid>eNp9UU1P3DAQtVArQMAf6AFZ6tkwtpPYuVSqUPmQkLjA2XKS8RLY2Fvbabv_vl52S-GCLx75vXkzz4-QLxzOOEh9nipet5qBAFa3Tc2Z2iOHAqqaCSnEpzf1ATlJ6QnKqUVb8XafHEgBGkQjDsn9zeKKXfZ0sVz3Ia2XNo_B0w5diEitH6h1GSONY57_jJPtaI5o84Q-09HTcZpmjzQ_xjB1oV_nsEI_2mPy2dllwpPdfUQeLn_cX1yz27urm4vvt6yvqzYzJ6xzrhs2ewHqTjjOe6ehVqJRjVZSW6vQtQ3AUJiVQ6f14JRS0FhwjTwibKubfuNq7swqlhXj2gQ7mt3Tc6nQVEpKvuF_2_ILMuHQFxfRLt-1vUf8-GgW4ZdRIMuXqSLwdScQw88ZUzZPYY6-eDRC1q1UUFVQWGLL6mNIKaJ7ncDBbMIz2_BMCc-8hGc20qdvd3tt-RdVIcid2QL5Bcb_sz-Q_QtJ6Kes</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2359370440</pqid></control><display><type>article</type><title>IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia</title><source>MEDLINE</source><source>Nature Free</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>SWEPUB Freely available online</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Schmidt, David E. ; de Haan, Noortje ; Sonneveld, Myrthe E. ; Porcelijn, Leendert ; van der Schoot, C. Ellen ; de Haas, Masja ; Zwaginga, Jaap-Jan ; Wuhrer, Manfred ; Vidarsson, Gestur</creator><creatorcontrib>Schmidt, David E. ; de Haan, Noortje ; Sonneveld, Myrthe E. ; Porcelijn, Leendert ; van der Schoot, C. Ellen ; de Haas, Masja ; Zwaginga, Jaap-Jan ; Wuhrer, Manfred ; Vidarsson, Gestur</creatorcontrib><description>The interactions of antibodies with myeloid Fcγ receptors and the complement system are regulated by an Asn297-linked glycan in the Fc portion of IgG. Alterations of serum IgG-Fc glycosylation have been reported in various autoimmune diseases, and correlate with treatment response and disease activity. We hypothesized that IgG-Fc glycosylation is altered in immune thrombocytopenia (ITP) and associates with response to anti-CD20 monoclonal antibody treatment (rituximab). IgG-Fc glycosylation was analyzed by liquid chromatography-mass spectrometry. We found that IgG-Fc glycosylation was identical between refractory ITP patients (HOVON64 trial; N = 108) and healthy controls (N = 120). Two months after rituximab treatment, we observed a shift in Fc glycosylation, with a mean 1.7% reduction in galactosylation for IgG1 and IgG4 and a mean 1.5% increase for bisection in IgG1, IgG2/3 and IgG4 (adjusted p < 1.7 × 10
−3
and p < 2 × 10
−4
, respectively). Neither baseline nor longitudinal changes in IgG-Fc glycosylation after rituximab were associated with clinical treatment response. We conclude that IgG-Fc glycosylation in refractory ITP is similar to healthy controls and does not predict treatment responses to rituximab. The observed changes two months after treatment suggest that rituximab may influence total serum IgG-Fc glycosylation. Overall, our study suggests that the pathophysiology of refractory ITP may differ from other autoimmune diseases.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-59651-7</identifier><identifier>PMID: 32080262</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/2152/2153/1291 ; 631/250/38 ; 692/308/575 ; 692/4017 ; Adult ; Autoimmune diseases ; Case-Control Studies ; CD20 antigen ; Complement system ; Female ; Glycosylation ; Humanities and Social Sciences ; Humans ; Idiopathic thrombocytopenic purpura ; Immunoglobulin Fc Fragments - metabolism ; Immunoglobulin G ; Immunoglobulin G - metabolism ; Immunotherapy ; Liquid chromatography ; Male ; Mass spectrometry ; Mass spectroscopy ; Middle Aged ; Monoclonal antibodies ; multidisciplinary ; Purpura, Thrombocytopenic, Idiopathic - drug therapy ; Rituximab ; Rituximab - pharmacology ; Rituximab - therapeutic use ; Science ; Science (multidisciplinary) ; Thrombocytopenia</subject><ispartof>SCIENTIFIC REPORTS, 2020-02, Vol.10 (1), p.3051, Article 3051</ispartof><rights>The Author(s) 2020</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-f2afffbd05290e8b2f11cf805726768738aa7ef9600daff4fef88df77706a0f63</citedby><cites>FETCH-LOGICAL-c549t-f2afffbd05290e8b2f11cf805726768738aa7ef9600daff4fef88df77706a0f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033207/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033207/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32080262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:144528438$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmidt, David E.</creatorcontrib><creatorcontrib>de Haan, Noortje</creatorcontrib><creatorcontrib>Sonneveld, Myrthe E.</creatorcontrib><creatorcontrib>Porcelijn, Leendert</creatorcontrib><creatorcontrib>van der Schoot, C. Ellen</creatorcontrib><creatorcontrib>de Haas, Masja</creatorcontrib><creatorcontrib>Zwaginga, Jaap-Jan</creatorcontrib><creatorcontrib>Wuhrer, Manfred</creatorcontrib><creatorcontrib>Vidarsson, Gestur</creatorcontrib><title>IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia</title><title>SCIENTIFIC REPORTS</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>The interactions of antibodies with myeloid Fcγ receptors and the complement system are regulated by an Asn297-linked glycan in the Fc portion of IgG. Alterations of serum IgG-Fc glycosylation have been reported in various autoimmune diseases, and correlate with treatment response and disease activity. We hypothesized that IgG-Fc glycosylation is altered in immune thrombocytopenia (ITP) and associates with response to anti-CD20 monoclonal antibody treatment (rituximab). IgG-Fc glycosylation was analyzed by liquid chromatography-mass spectrometry. We found that IgG-Fc glycosylation was identical between refractory ITP patients (HOVON64 trial; N = 108) and healthy controls (N = 120). Two months after rituximab treatment, we observed a shift in Fc glycosylation, with a mean 1.7% reduction in galactosylation for IgG1 and IgG4 and a mean 1.5% increase for bisection in IgG1, IgG2/3 and IgG4 (adjusted p < 1.7 × 10
−3
and p < 2 × 10
−4
, respectively). Neither baseline nor longitudinal changes in IgG-Fc glycosylation after rituximab were associated with clinical treatment response. We conclude that IgG-Fc glycosylation in refractory ITP is similar to healthy controls and does not predict treatment responses to rituximab. The observed changes two months after treatment suggest that rituximab may influence total serum IgG-Fc glycosylation. Overall, our study suggests that the pathophysiology of refractory ITP may differ from other autoimmune diseases.</description><subject>631/250/2152/2153/1291</subject><subject>631/250/38</subject><subject>692/308/575</subject><subject>692/4017</subject><subject>Adult</subject><subject>Autoimmune diseases</subject><subject>Case-Control Studies</subject><subject>CD20 antigen</subject><subject>Complement system</subject><subject>Female</subject><subject>Glycosylation</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Idiopathic thrombocytopenic purpura</subject><subject>Immunoglobulin Fc Fragments - metabolism</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - metabolism</subject><subject>Immunotherapy</subject><subject>Liquid chromatography</subject><subject>Male</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>multidisciplinary</subject><subject>Purpura, Thrombocytopenic, Idiopathic - drug therapy</subject><subject>Rituximab</subject><subject>Rituximab - pharmacology</subject><subject>Rituximab - therapeutic use</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Thrombocytopenia</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>D8T</sourceid><recordid>eNp9UU1P3DAQtVArQMAf6AFZ6tkwtpPYuVSqUPmQkLjA2XKS8RLY2Fvbabv_vl52S-GCLx75vXkzz4-QLxzOOEh9nipet5qBAFa3Tc2Z2iOHAqqaCSnEpzf1ATlJ6QnKqUVb8XafHEgBGkQjDsn9zeKKXfZ0sVz3Ia2XNo_B0w5diEitH6h1GSONY57_jJPtaI5o84Q-09HTcZpmjzQ_xjB1oV_nsEI_2mPy2dllwpPdfUQeLn_cX1yz27urm4vvt6yvqzYzJ6xzrhs2ewHqTjjOe6ehVqJRjVZSW6vQtQ3AUJiVQ6f14JRS0FhwjTwibKubfuNq7swqlhXj2gQ7mt3Tc6nQVEpKvuF_2_ILMuHQFxfRLt-1vUf8-GgW4ZdRIMuXqSLwdScQw88ZUzZPYY6-eDRC1q1UUFVQWGLL6mNIKaJ7ncDBbMIz2_BMCc-8hGc20qdvd3tt-RdVIcid2QL5Bcb_sz-Q_QtJ6Kes</recordid><startdate>20200220</startdate><enddate>20200220</enddate><creator>Schmidt, David E.</creator><creator>de Haan, Noortje</creator><creator>Sonneveld, Myrthe E.</creator><creator>Porcelijn, Leendert</creator><creator>van der Schoot, C. Ellen</creator><creator>de Haas, Masja</creator><creator>Zwaginga, Jaap-Jan</creator><creator>Wuhrer, Manfred</creator><creator>Vidarsson, Gestur</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20200220</creationdate><title>IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia</title><author>Schmidt, David E. ; de Haan, Noortje ; Sonneveld, Myrthe E. ; Porcelijn, Leendert ; van der Schoot, C. Ellen ; de Haas, Masja ; Zwaginga, Jaap-Jan ; Wuhrer, Manfred ; Vidarsson, Gestur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-f2afffbd05290e8b2f11cf805726768738aa7ef9600daff4fef88df77706a0f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/250/2152/2153/1291</topic><topic>631/250/38</topic><topic>692/308/575</topic><topic>692/4017</topic><topic>Adult</topic><topic>Autoimmune diseases</topic><topic>Case-Control Studies</topic><topic>CD20 antigen</topic><topic>Complement system</topic><topic>Female</topic><topic>Glycosylation</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Idiopathic thrombocytopenic purpura</topic><topic>Immunoglobulin Fc Fragments - metabolism</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - metabolism</topic><topic>Immunotherapy</topic><topic>Liquid chromatography</topic><topic>Male</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>multidisciplinary</topic><topic>Purpura, Thrombocytopenic, Idiopathic - drug therapy</topic><topic>Rituximab</topic><topic>Rituximab - pharmacology</topic><topic>Rituximab - therapeutic use</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Thrombocytopenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmidt, David E.</creatorcontrib><creatorcontrib>de Haan, Noortje</creatorcontrib><creatorcontrib>Sonneveld, Myrthe E.</creatorcontrib><creatorcontrib>Porcelijn, Leendert</creatorcontrib><creatorcontrib>van der Schoot, C. Ellen</creatorcontrib><creatorcontrib>de Haas, Masja</creatorcontrib><creatorcontrib>Zwaginga, Jaap-Jan</creatorcontrib><creatorcontrib>Wuhrer, Manfred</creatorcontrib><creatorcontrib>Vidarsson, Gestur</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>SCIENTIFIC REPORTS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmidt, David E.</au><au>de Haan, Noortje</au><au>Sonneveld, Myrthe E.</au><au>Porcelijn, Leendert</au><au>van der Schoot, C. Ellen</au><au>de Haas, Masja</au><au>Zwaginga, Jaap-Jan</au><au>Wuhrer, Manfred</au><au>Vidarsson, Gestur</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia</atitle><jtitle>SCIENTIFIC REPORTS</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-02-20</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>3051</spage><pages>3051-</pages><artnum>3051</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>The interactions of antibodies with myeloid Fcγ receptors and the complement system are regulated by an Asn297-linked glycan in the Fc portion of IgG. Alterations of serum IgG-Fc glycosylation have been reported in various autoimmune diseases, and correlate with treatment response and disease activity. We hypothesized that IgG-Fc glycosylation is altered in immune thrombocytopenia (ITP) and associates with response to anti-CD20 monoclonal antibody treatment (rituximab). IgG-Fc glycosylation was analyzed by liquid chromatography-mass spectrometry. We found that IgG-Fc glycosylation was identical between refractory ITP patients (HOVON64 trial; N = 108) and healthy controls (N = 120). Two months after rituximab treatment, we observed a shift in Fc glycosylation, with a mean 1.7% reduction in galactosylation for IgG1 and IgG4 and a mean 1.5% increase for bisection in IgG1, IgG2/3 and IgG4 (adjusted p < 1.7 × 10
−3
and p < 2 × 10
−4
, respectively). Neither baseline nor longitudinal changes in IgG-Fc glycosylation after rituximab were associated with clinical treatment response. We conclude that IgG-Fc glycosylation in refractory ITP is similar to healthy controls and does not predict treatment responses to rituximab. The observed changes two months after treatment suggest that rituximab may influence total serum IgG-Fc glycosylation. Overall, our study suggests that the pathophysiology of refractory ITP may differ from other autoimmune diseases.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32080262</pmid><doi>10.1038/s41598-020-59651-7</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | SCIENTIFIC REPORTS, 2020-02, Vol.10 (1), p.3051, Article 3051 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_473316 |
| source | MEDLINE; Nature Free; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; SWEPUB Freely available online; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals |
| subjects | 631/250/2152/2153/1291 631/250/38 692/308/575 692/4017 Adult Autoimmune diseases Case-Control Studies CD20 antigen Complement system Female Glycosylation Humanities and Social Sciences Humans Idiopathic thrombocytopenic purpura Immunoglobulin Fc Fragments - metabolism Immunoglobulin G Immunoglobulin G - metabolism Immunotherapy Liquid chromatography Male Mass spectrometry Mass spectroscopy Middle Aged Monoclonal antibodies multidisciplinary Purpura, Thrombocytopenic, Idiopathic - drug therapy Rituximab Rituximab - pharmacology Rituximab - therapeutic use Science Science (multidisciplinary) Thrombocytopenia |
| title | IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T03%3A12%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IgG-Fc%20glycosylation%20before%20and%20after%20rituximab%20treatment%20in%20immune%20thrombocytopenia&rft.jtitle=SCIENTIFIC%20REPORTS&rft.au=Schmidt,%20David%20E.&rft.date=2020-02-20&rft.volume=10&rft.issue=1&rft.spage=3051&rft.pages=3051-&rft.artnum=3051&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-59651-7&rft_dat=%3Cproquest_swepu%3E2359370440%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2359370440&rft_id=info:pmid/32080262&rfr_iscdi=true |